Concepedia

Gaétan Ladouceur

GL

Statistics

Publications

8

Citations

222

H-Index

8

Active since

1989

Affiliations

Bayer (United States)(Current)

Gaétan Ladouceur is an author at Bayer (United States) specializing in medicinal chemistry, pharmacology, and synthetic medicinal chemistry.

Publications per year

1989–2015

8

Publications

8

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer

Abhilasha Nair, Steven J. Lemery, Jun Yang et al. · Clinical Cancer Research · 2015 · 78 citations

, , +15

Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists

Gaétan Ladouceur, James H. Cook, Elizabeth M. Doherty et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 38 citations · Full text

, , +11

Synthesis and evaluation of [125I]-(S)-iodozacopride, a high affinity radioligand for 5HT3 receptors

Donald R. Gehlert, Douglas A. Schober, Susan L. Gackenheimer et al. · Neurochemistry International · 1993 · 28 citations

, , +8

Synthetic studies targeted at the cytotoxic 8,9-seco-ent-kaurene diterpenes. Concise complementary stereocontrolled construction of the bridgehead olefin core

Leo A. Paquette, Gaétan Ladouceur · The Journal of Organic Chemistry · 1989 · 26 citations

, , +6

Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis

Roger A. Smith, Donald L. Hertzog, Martin H. Osterhout et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 16 citations · Full text

, , +12

1–5 of 8